p53 constrains progression to anaplastic thyroid carcinoma in a Braf -mutant mouse model of papillary thyroid cancer

Abstract

Anaplastic thyroid carcinoma (ATC) has among the worst prognoses of any solid malignancy. The low incidence of the disease has in part precluded systematic clinical trials and tissue collection, and there has been little progress in developing effective therapies. v-raf murine sarcoma viral oncogene homolog B (BRAF) and tumor protein p53 (TP53) mutations cooccur in a high proportion of ATCs, particularly those associated with a precursor papillary thyroid carcinoma (PTC). To develop an adult-onset model of BRAF-mutant ATC, we generated a thyroid-specific CreER transgenic mouse. We used a Cre-regulated Braf V600E mouse and a conditional Trp53 allelic series to demonstrate that p53 constrains progression from PTC to ATC. Gene expression and immunohistochemical analyses of murine tumors identified the cardinal features of human ATC including loss of differentiation, local invasion, distant metastasis, and rapid lethality. We used small-animal ultrasound imaging to monitor autochthonous tumors and showed that treatment with the selective BRAF inhibitor PLX4720 improved survival but did not lead to tumor regression or suppress signaling through the MAPK pathway. The combination of PLX4720 and the mapk/Erk kinase (MEK) inhibitor PD0325901 more completely suppressed MAPK pathway activation in mouse and human ATC cell lines and improved the structural response and survival of ATC-bearing animals. This model expands the limited repertoire of autochthonous models of clinically aggressive thyroid cancer, and these data suggest that small-molecule MAPK pathway inhibitors hold clinical promise in the treatment of advanced thyroid carcinoma.vemurafenib | anaplastic thyroid cancer | MEK inhibitor | genetically-engineered mouse model

Cholesterol Enhances Colorectal Cancer Progression via ROS Elevation and MAPK Signaling Pathway Activation

“…EMT is the first step in metastasis, which is characterized by the loss of epithelial polarity and cell-cell adhesion and is a precursor to increased cell mobility. MAPKs are involved in cell migration and invasion, partially through regulation of focal adhesion kinase (FAK) and matrix metalloproteinases (MMPs) [36-38]. Previous studies have indicated that ROS could regulate PI3K/Akt and MAPK signaling pathways and thus be involved in apoptosis [39].…”

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib

“…We do know that mutant BRAF-mediated inhibition of iodine transport is only partially ERK dependent, inhibition of the MAPK pathway with a BRAF or MEK inhibitor does not completely restore iodine uptake, and the effects of either RAF or MEK inhibitors on downstream signaling in thyroid cancer cells may be limited by feedback mechanisms (15,16,23). An important area of future investigation will be to study BRAF inhibitors in combination with other inhibitors of the MAPK or feedback pathways to achieve even more robust radioactive iodine uptake in BRAF V600E-mutant, iodine-refractory PTC (24,25).…”

Anaplastic thyroid cancer – an overview of genetic variations and treatment modalities

“…[66][67][68][69] In the recent past, a number of transgenic mice have been developed that mimic ATC in vivo [70][71][72][73] and serve as much more clinically relevant models for preclinical testing. These models have primarily been used to elucidate the hypothesis that ATCs arise as a progression from PTC or FTC due to hits to multiple signaling pathways and therefore provide the closest simulation environment reflective of direct in human testing.…”